Sam Brusco, Associate Editor04.07.22
Integer Holdings Corporation has acquired Connemara Biomedical Holdings Teoranta, which includes operating subsidiaries Aran Biomedical and Proxy Biomedical (collectively, “Aran”). Aran develops proprietary medical textiles, biomaterial coverings and coatings, and metal/polymer braiding.
The transaction was valued at 120 million Euros, or about $131 million.
The Galway, Ireland-based company increases Integer’s portfolio for complex delivery and therapeutic devices for structural heart, neurovascular, peripheral vascular, endovascular, and general surgery.
“The acquisition of Aran Biomedical is entirely aligned with our strategy to expand our presence in high growth markets,” Joe Dziedzic, Integer president and CEO told the press. “Aran brings subject matter expertise and highly differentiated implant technology solutions to our portfolio. Coupling these technology solutions and expertise with Integer’s leadership in delivery systems and manufacturing scale will bring an unparalleled ability to meet our customers’ needs and be their partner of choice for developing the next generation of lifesaving and life-enhancing medical devices. Their innovation, capabilities and values are a perfect complement to Integer’s, and we are thrilled to welcome Aran’s 130 associates to the Integer team.”
Peter Mulrooney, Aran Biomedical CEO, added, “We are very excited and proud to be joining Integer, one of the largest medical device outsource manufacturers in the world. Combining Aran Biomedical’s proprietary biomaterial implant technologies with Integer’s world class delivery systems will lead to a more highly differentiated service offering to the medical device industry.”
Aran earned $17 million in revenue in 2021, almost doubling sales from the previous year.
The transaction was valued at 120 million Euros, or about $131 million.
The Galway, Ireland-based company increases Integer’s portfolio for complex delivery and therapeutic devices for structural heart, neurovascular, peripheral vascular, endovascular, and general surgery.
“The acquisition of Aran Biomedical is entirely aligned with our strategy to expand our presence in high growth markets,” Joe Dziedzic, Integer president and CEO told the press. “Aran brings subject matter expertise and highly differentiated implant technology solutions to our portfolio. Coupling these technology solutions and expertise with Integer’s leadership in delivery systems and manufacturing scale will bring an unparalleled ability to meet our customers’ needs and be their partner of choice for developing the next generation of lifesaving and life-enhancing medical devices. Their innovation, capabilities and values are a perfect complement to Integer’s, and we are thrilled to welcome Aran’s 130 associates to the Integer team.”
Peter Mulrooney, Aran Biomedical CEO, added, “We are very excited and proud to be joining Integer, one of the largest medical device outsource manufacturers in the world. Combining Aran Biomedical’s proprietary biomaterial implant technologies with Integer’s world class delivery systems will lead to a more highly differentiated service offering to the medical device industry.”
Aran earned $17 million in revenue in 2021, almost doubling sales from the previous year.